ストックスクリーナーアプリを入手
2.19
9.50%
0.19
アフターアワーズ：
2.17
-0.02
-0.91%
前日終値:
$2.00
開ける：
$1.95
24時間の取引高:
1.19M
Relative Volume:
1.93
時価総額：
$232.58M
収益：
-
当期純損益:
$-31.64M
株価収益率:
-5.1822
EPS:
-0.4226
ネットキャッシュフロー:
$-13.98M
1週間 パフォーマンス:
+26.59%
1か月 パフォーマンス:
-38.57%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.92
$2.20
1週間の範囲:
$1.71
$2.20
52週間の値動き範囲:
$1.70
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
2.19 | 197.54M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-27 | 開始されました | H.C. Wainwright | Buy |
Nervgen Pharma Corp (NGEN) 最新ニュース
NervGen rises as TD Cowen issues new BUY on lead asset - MSN
NervGen Pharma Corp. Financial Disclosures & SEC Filings - TradingView
NervGen Pharma (NGEN) Investor Relations, Earnings Summary & Outlook - Quartr
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally - GuruFocus
NervGen stock rises as TD Cowen issues new Buy (NGEN:NASDAQ) - Seeking Alpha
NervGen stock initiated at Buy by TD Cowen ahead of phase 3 trial - Investing.com UK
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
NGENNervGen Pharma Corp. stock news, filings & ratings - Quantisnow
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program - TipRanks
United StatesMintz Advises On NervGen Pharma’s $60 Million Public Offering - Mondaq
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors - TipRanks
Biopharma Company Reveals High-Impact SCI Recovery Gains - Streetwise Reports
NGEN Stock Price and Chart — NASDAQ:NGEN - TradingView
NervGen Pharma Company Profile & Introduction - Moomoo
These stocks have an unusual volume in today's session - ChartMill
NervGen reports positive gait analysis data for NVG-291 trial - grafa.com
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results - GuruFocus
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
NervGen reports positive gait analysis data for NVG-291 trial By Investing.com - Investing.com Australia
NervGen Pharma Corp. Announces Positive Independent Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery With NVG-291 In Phase 1b/2a CONNECT SCI Study - marketscreener.com
NervGen Pharma Reports Positive Biomechanical Gait Analysis Results for NVG-291 Demonstrating Genuine Neural Recovery in Chronic Tetraplegia - Quiver Quantitative
Spinal cord injury trial: NervGen drug improves walking control - Stock Titan
Assessing NervGen Pharma (NasdaqCM:NGEN) Valuation After Its $60 Million Follow On Equity Offering - Sahm
NervGen Pharma Raises Capital to Advance Therapy for Spinal Cord Injury - techcouver.com
NervGen launches underwritten public offering of shares and warrants - MSN
NGEN Slides As NervGen Pharma Dilution Hits Share Price - timothysykes.com
NervGen Pharma prices 24M share public offering; warrants exercisable at $3.68 - MSN
NervGen Pharma Prices $60 Million Share Offering - Moomoo
HC Wainwright & Co. initiates coverage of NervGen Pharma (NGEN) with buy recommendation - MSN
NGEN: Joint Book Runners for Recent Offering Announced - GuruFocus
NervGen Pharma Shares Continue Sliding on Size of $60 Million Share Sale - Moomoo
Keep an eye on the top gainers and losers in Friday's session. - ChartMill
Biggest stock movers Friday: Quantum computing stocks, WDAY, ZM, and more - Seeking Alpha
NervGen Pharma stock tumbles on dilutive share offering By Investing.com - Investing.com India
NervGen Pharma, Medline, sociétés minières d'argent - TradingView
NervGen Pharma stock tumbles on dilutive share offering - Investing.com
Nervgen Pharma Corp (NGEN) 財務データ
収益
当期純利益
現金流量
EPS
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):